The power of EPKINLY makes remission possible

For diffuse large B-cell lymphoma (DLBCL) that returned or didn’t respond after 2 or more prior treatments

In a clinical study of 148 patients receiving EPKINLY, 61% (90 patients) achieved remission: complete remission in 38% (56 patients) and partial remission in 23% (34 patients).

EPKINLY is approved based on patient response data. A study is ongoing to confirm clinical benefit of EPKINLY.

Actor portrayals.

Help us guide you

What are you most interested in learning about as you consider DLBCL treatments?

See how EPKINLY has worked for others.

Learn about EPKINLY study results

Learn about the side effects of treatment with EPKINLY.

Learn about EPKINLY safety

How EPKINLY injections are given.

See how you receive EPKINLY

EPKINLY works by harnessing the power of your own immune system to fight cancer.

See EPKINLY in action

Patient Support

We are dedicated to providing useful tools and resources to meet your needs, including financial support and preparing for your appointments.

Care Partner Support

We are dedicated to helping you find tools to meet your needs as a Care Partner and help you provide support to your loved one on treatment with EPKINLY.